WHAT IS CLAIMED IS:

1. A composition comprising danirixin in combination with a neuraminidase inhibitor compound.

2. A composition comprising danirixin in combination with zanamivir.

3. A composition comprising danirixin in combination with oseltamivir.

4. A composition comprising danirixin in combination with ribavirin.

5. A composition comprising danirixin in combination with favipiravir.

6. A composition comprising danirixin in combination with one or more antimicrobial agents selected from Table 4.

7. A pharmaceutical composition comprising danirixin in combination with a neuraminidase inhibitor compound and a pharmaceutically acceptable excipient.

8. A pharmaceutical composition comprising danirixin in combination with zanamivir and a pharmaceutically acceptable excipient.

9. A pharmaceutical composition comprising danirixin in combination with oseltamivir and a pharmaceutically acceptable excipient.

10. A pharmaceutical composition comprising danirixin in combination with ribavirin and a pharmaceutically acceptable excipient.

11. A pharmaceutical composition comprising danirixin in combination with one or more antimicrobial agents selected from Table 4 and a pharmaceutically acceptable excipient.

12. Use of danirixin in combination with a neuraminidase inhibitor compound in the manufacture of a medicament for treating a respiratory infectious disease in a subject.

13. Use of danirixin in combination with zanamivir in the manufacture of a medicament for treating a respiratory infectious disease in a subject.

14. Use of danirixin in combination with oseltamivir in the manufacture of a medicament for treating a respiratory infectious disease in a subject.

15. Use of danirixin in combination with ribavirin in the manufacture of a medicament for treating a respiratory infectious disease in a subject.

16. Use of danirixin in combination with favipiravir in the manufacture of a medicament for treating a respiratory infectious disease in a subject.

17. Use of danirixin in combination with one or more antimicrobial agents selected from Table 4 in the manufacture of a medicament for treating a respiratory infectious disease in a subject.

18. The use according to claims 12-17, wherein the respiratory infectious disease is influenza.

19. The use according to claims 12-17, wherein the respiratory infectious disease is RSV.

20. The use according to claims 12-17, wherein the combination of danirixin and neuraminidase inhibitor compound are to be administered in the same dosage form.

21. The use according to claims 12-17, wherein the combination of danirixin and neuraminidase inhibitor compound are to be administered simultaneously.

22. The use according to claims 12-17, wherein the combination of danirixin and neuraminidase inhibitor compound are to be administered separately.

23. The use according to claims 12-17, wherein the combination of danirixin and neuraminidase inhibitor compound are to be administered in the same dosage form.

24. The use according to claims 12-17, wherein the combination of the compound of danirixin and neuraminidase inhibitor compound are to be administered simultaneously.

25. The use according to claims 12-17, wherein the combination of danirixin and neuraminidase inhibitor compound are to be administered separately.

26. The use according to claim 15, wherein the combination of danirixin and ribavirin are to be administered in the same dosage form.

27. The use according to claim 15, wherein the combination of the compound of danirixin and ribavirin are to be administered simultaneously.

28. The use according to claim 15, wherein the combination of danirixin and ribavirin are to be administered separately.

29. Use of danirixin in the manufacture of a medicament for treating influenza in a subject.

30. Use of danirixin in the manufacture of a medicament for treating RSV in a subject.

31. A pharmaceutical composition for intravenous administration comprising: danirixin as a hydrobromide salt in aqueous solution.

32. A pharmaceutical composition for intravenous administration comprising: danirixin as a hydrobromide salt and a pharmaceutically acceptable excipient in aqueous solution.

33. The pharmaceutical composition according to claim 32, wherein the pharmaceutically acceptable excipient comprises β-cyclodextrin.

34. The pharmaceutical composition according to claim 32, wherein the pharmaceutically acceptable excipient comprises sulfobutylether.

35. The pharmaceutical composition according to claim 32, wherein the pharmaceutically acceptable excipient comprises β-cyclodextrin and sulfobutylether.

36. The pharmaceutical composition according to claim 32, wherein the pharmaceutically acceptable excipient comprises Captisol®.

37. Use of the pharmaceutical composition according to any of claims 31-36 in the manufacture of a medicament for treating a respiratory infectious disease in a subject.

38. Use of the pharmaceutical composition according to any of claims 31-36 in the manufacture of a medicament for treating RSV in a subject.

39. Use of the pharmaceutical composition according to any of claims 31-36 in the manufacture of a medicament for treating influenza in a subject.

40. Use of danirixin in combination with Palivizumab in the manufacture of a medicament for treating RSV in a subject.

41. The use according to claim 40, wherein the combination of danirixin and Palivizumab are to be administered simultaneously.

42. The use according to claim 40, wherein the combination of danirixin and Palivizumab are to be administered separately.